Dr Reddy's Labs launches Lansoprazole DR Orally Disintegrating Tablets in US

Published On 2021-02-22 09:44 GMT   |   Update On 2021-02-22 10:04 GMT

Hyderabad and Princeton: Dr. Reddy's Laboratories Ltd. today announced the launch of Lansoprazole DR Orally Disintegrating Tablets in US.

The product is a therapeutic equivalent generic version of Prevacid SoluTab Delayed- Release Orally Disintegrating Tablets, 15 mg and 30 mg, approved by the U.S. Food and Drug Administration (USFDA).

The Prevacid brand and generic had U.S. sales of approximately $87 million MAT for the most recent twelve months ending in December 2020 according to IMS Health*.
Dr. Reddy's Lansoprazole DR Orally Disintegrating Tablets are available in 15 mg and 30 mg tablets in unit-dose packages of 100 (10 x 10).
Prevacid is a trademark of Takeda Pharmaceuticals U.S.A., Inc.

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, committed to providing affordable and innovative medicines for healthier lives.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News